Wilder,
Correct, it is membrane bound serine protease.
<< PK before P2b in ACS? I listened to last CC and CIBC, and PK trial was not mentioned AT ALL. That is a shock, and tells me this company is now very afraid.>>
No, it is not mentioned and none asked about.
Company is not very afraid. This trial MUST be done before changing administration route, from S.C. to bolus i.v, for PII/IIb in UA. You do remember that DVT and Elective Angioplasty was with subcutaneous very small (3.5-10.0 mcg/kg) doses. If you did investigate MEDI/BTRN Amevine i.v. versus S.C. PK (and efficacy) you should observed huge difference and unpredictable performance. To select RIGHT i.v. doses (by now CVAS should know what is correct safe/therapeutic drug blood level) they need i.v. PK (healthy volunteers). It does sound OK that they are going after UA.
They started this Pib in November (I think, but to be sure you should contact CVAS IR), and by now they should have needed data. I am expecting that they will be able to start PIIb in October, but who knows?
Regards the BVF, Lampert was very skeptical on rNIF after PIIa. So, he did surprise me very much when he continued buying CVAS in front of uncertainty of the stroke trial outcome. He has *strange* trading philosophy, and he move when one expect the less.
Somehow (for some unclear reasons, even to me <grrr>) I think that PFE is not yet ready to give up on rNIF. MI perfusion injury and some other cardiovascular events may benefit from anti-inflammatory drug like rNIF.
I am very, very stubborn with CVAS. Can not accept that RW trick me out. I am holding full position, and am averaging down. Total burst,… or make few bucks.
Miljenko |
